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Abstract
Purpose Head and neck squamous cell carcinoma (HNSCC)
may cause a decreased apparent diffusion coefficient (ADC)
on diffusion-weighted magnetic resonance imaging (DW
MRI) and an increased standardized uptake value (SUV) on
fluorodeoxyglucose (FDG) positron emission tomography
(PET/CT). We analysed the reproducibility of ADC and
SUV measurements in HNSCC and evaluated whether these
biomarkers are correlated or independent.
Methods This retrospective analysis of DW MRI and FDG
PET/CT data series included 34 HNSCC in 33 consecutive
patients. Two experienced readers measured tumour ADC
and SUV values independently. Statistical comparison and
correlation with histopathology was done. Intra- and
inter-observer agreement for ADC and SUV measurements
was assessed.
Results Intraclass correlation coefficient (ICC) analysis
showed almost perfect reproducibility (>0.90) for ADCmean,
ADCmin, SUVmax and SUVmean values for intra-observer
and inter-observer agreement. Mean ADCmean and ADCmin
in HNSCC were 1.05±0.34 × 10−3mm2/s and 0.65±0.29 ×
10−3mm2/s, respectively. Mean SUVmean and mean SUVmax
were 7.61±3.87 and 12.8±5.0, respectively. Although
statistically not significant, a trend towards higher
SUV and lower ADC was observed with increasing
tumour dedifferentiation. Pearson’s correlation analysis
showed no significant correlation between ADC and
SUV measurements (r −0.103, −0.051; p 0.552, 0.777).
Conclusion Our data suggest that ADC and SUV values are
reproducible and independent biomarkers in HNSCC.
Keywords Carcinoma, squamous cell of head and neck .
Diffusion-weighted magnetic resonance imaging . Positron
emission tomography and computed tomography .Molecular
imaging . Neoplasms
Introduction
Over 90 % of malignant head and neck tumours in adults are
squamous cell carcinomas (HNSCC) [1]. Appropriate assess-
ment of superficial and deep tumour spread, regional lymph-
adenopathy and distant metastases is essential for staging and
therapeutic planning. According to the guidelines of the Inter-
national Union Against Cancer (UICC) and American Joint
Committee on Cancer (AJCC), tumour staging requires en-
doscopy with biopsy and additional imaging [1].
Morphologic evaluation is preferably done with contrast-
enhanced CT or MRI. However, fluorodeoxyglucose (FDG)
positron emission tomography (PET/CT) and diffusion-
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weighted MR imaging (DW MRI) are increasingly used in
oncologic head and neck imaging in order to add diagnostic
information beyond morphology [2, 3]. Although each
modality is based on different physical principles, both
modalities may be seen as functional imaging tools as they
allow interrogation of tissue with regard to certain biologic
properties. FDG PET/CT measures increased cellular glucose
metabolism as expressed by the standardized uptake value
(SUV). In oncologic imaging, increased SUV may be seen
as a sign of increased cell proliferation [1–4] and may also
correlate with the degree of tumour necrosis [5]. The principle
of DWMRI as a functional biomarker is based on the assess-
ment of random (Brownian) motion of extracellular water
molecules, which is restricted in hypercellular tumour tissue,
as expressed by the decreased apparent diffusion coefficient
(ADC) value. In addition, ADC values may also reflect cell
proliferation [6, 7] and may be affected by the presence of
tumour necrosis [8]. Based on previous studies it appears that
most HNSCC have lower ADC values than normal tissue
because of their higher cellular density [8].
Since both increased SUVand decreased ADC values are
seen in the context of neoplasia although they refer to
different biologic phenomena, it would be of interest to
know whether these parameters are statistically correlated
or independent in order to facilitate their use in diagnostic
interpretation. Previous studies in different tumour types
have found diverging results. An inverse correlation was
recently demonstrated between SUV and ADC values in
gastrointestinal stromal tumours [9], lung cancer [10] and
in cervical cancer [11], whereas no correlation was found in
lymphoma [12]. To the best of our knowledge, only three
reports have so far compared SUV and ADC values in
HNSCC. The results were diverging with either significant
correlation or no correlation [13–15]. It also remains open
whether SUV and ADC measurements are reproducible in
HNSCC due to the paucity of reported data [16, 17].
The purpose of the current study was to assess the
reproducibility of ADC and SUV measurements in
patients with biopsy-proven HNSCC and to evaluate
whether ADC and SUV values are statistically correlated or
independent functional parameters.
Materials and methods
Study design and patient selection
This retrospective study was approved by the Institutional
Ethics Committee and was performed in accordance with
the guidelines of the Helsinki II Declaration. Informed con-
sent was waived. Inclusion criteria were: adult patients with
histologically proven HNSCC, who had undergone whole-
body FDG PET/CT and high-resolution head and neck DW
MRI prior to treatment (mean delay between the two exams
= 3.5 days) and who were subsequently treated with surgery,
radio(chemo)therapy or a combination of the two. A com-
puterized search of the PACS archives and medical records
of our institution retrospectively identified 34 consecutive
patients who fulfilled the above-mentioned inclusion crite-
ria. One patient had to be excluded from the study because
of poor DW MRI image quality due to metal implants
causing major image distortion. Therefore, 33 patients
formed the basis of the current study (22 men and 11 women
with a mean age of 54.7 years; range 16–77 years). One
patient had two synchronous HNSCC resulting in a total of
34 evaluated tumours. In 24 patients, the indication for
imaging was primary staging of HNSCC; in 10 patients,
the indication was follow-up or suspected recurrence
45 months (range 10–95 months) after surgery ± radiotherapy.
Primary tumour sites were as follows: oropharynx (n=13),
hypopharynx (n=6), oral cavity (n=6), larynx (n=3), naso-
pharynx (n=3), parotid gland (n=2) and paranasal sinuses
(n=1). Tumour size assessed by the longest diameter mea-
sured in the axial plane according to RECISTcriteria was 32±
14 mm (range 15–64 mm). Of the tumours, 8 were poorly
differentiated or undifferentiated, 21 were moderately differ-
entiated and 5 were well differentiated. There were one T1,
four T2, five T3 and fourteen T4 primary tumours and four
T1, two T2, two T3 and two T4 recurrent tumours.
PET/CT acquisition
All PET/CT examinations were performed on an integrated
PET/CT scanner (Biograph 16-slice PET/CT scanner, Sie-
mens Healthcare, Erlangen, Germany). Prior to the exam, all
patients had fasted for at least 6 h and the measured intra-
venous serum glucose concentration prior to study initiation
was less than 8.5 mmol/l. PET data acquisition was started
60 min after injection of 370 MBq of 18F-FDG with 3 min
per bed position for a total of 7 to 9 beds, from the vertex to
the proximal thigh. CT data acquisition for attenuation cor-
rection was performed using the following parameters:
120 kV, 180 mAs, 16×1.5 collimation, pitch = 1.2, 1 s per
rotation. PET image reconstruction was done using an
attenuation-weighted ordered subset expectation maximiza-
tion (AWOSEM) iterative reconstruction algorithm with a
matrix of 168×168 and a slice thickness of 5 mm. The
reconstruction parameters were set to the default values
(four iterations, eight subsets, and a post-processing Gauss-
ian kernel with a full-width at half-maximum of 5 mm). The
SUV was calculated by using the standard formula normal-
ized by body weight: SUV=cdc/(di/w), where cdc is the
decay-corrected tracer tissue concentration (Bq/g), di is the
injected dose (Bq), and w is the patient’s body weight (g)
[18]. In addition, high-resolution, contrast-enhanced CT,
which is part of the routine PET/CT protocol for HNSCC
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in our institution, was obtained after intravenous administration
of 2 ml/kg of iohexol (Accupaque 350®, GE Healthcare SA,
Opfikon, Switzerland) in all patients.
MRI acquisition
The MRI examinations were performed with dedicated head
and neck coils on a 1.5 T Espree machine (Siemens Health-
care, Erlangen, Germany) in 23 patients and on a 3 T Trio
(Siemens Healthcare, Erlangen, Germany) in 11 patients.
The MRI protocol on both machines included axial T2-
weighted, axial T1-weighted and axial diffusion-weighted
imaging (DWI) sequences obtained before intravenous in-
jection of contrast material followed by an axial T1-
weighted sequence after contrast material application
(gadobenate dimeglumine, Multihance®, Bracco Diagnos-
tics, Milan, Italy). Depending on tumour location, additional
T1-weighted sequences with fat saturation were then
obtained in the coronal and/or sagittal plane. DWI was
performed using a single-shot echo planar technique with
fat suppression on both machines (repetition time ms/echo
time ms, TR/TE=3,200/86 and TR/TE=2,200/63, respec-
tively, 40 sections, slice thickness = 5 mm, intersection gap
= 1.5 mm, field of view = 230×230 mm, matrix = 128×128,
3 acquired signals, pixel resolution = 1.8×1.8×5.0 mm,
acquisition time = 3 min 02 s and 3 min 17 s, respective-
ly). Two b values were applied: 0 and 1,000 s/mm2. DWI
images were acquired in three orthogonal directions and
then combined into a single trace image. ADC maps were
calculated automatically by the MRI software using the
following formula: ADC (mm2/s)=-ln (S2/S1)/(b2-b1), with
b1=0 and b2=1,000. The parameters for the fast spin echo
T2- weighted sequence at 1.5 and 3 T were as follows:
TR/TE=3,300/106 and TR/TE=3,010/82, respectively, 24
sections, slice thickness = 4 mm, intersection gap = 0.8 mm,
field of view = 230×180 mm, matrix = 512×416, three
acquired signals, pixel resolution = 0.4×0.4×4.0 mm, ac-
quisition time =3 min 30 s and 4 min 20 s, respectively).
The fast spin echo T1-weighted sequences performed before
and after intravenous injection of contrast material at 1.5 and
3 T had the following parameters: TR/TE=771/11 and
TR/TE=687/9, respectively, 30 slices, slice thickness =
3 mm, intersection gap = 0.6 mm, field of view = 230×
230 mm, matrix = 512×512, two acquired signals, pixel
resolution = 0.4×0.4×4.0 mm, acquisition time = 3 min 56 s
and 4 min 36 s, respectively). In order to obtain good MRI
image quality, all patients were carefully instructed to re-
frain from vigorous swallowing or breathing during image
acquisition, in particular during the acquisition of DWI
sequences. Small breaks were made between individual
sequences, so as to allow patients to clear the throat of
mucous secretions, to cough and to swallow between the
sequences.
Image evaluation, ADC and SUV measurements
All images were analysed by two independent readers who
evaluated both data sets (MRI including DW MRI and
PET/CT). One reader was a board-certified nuclear medicine
specialist with additional expertise in head and neck MRI, and
the second reader was a board-certified head and neck radiolo-
gist with additional expertise in PET/CT. Defined criteria were
used for each modality and both readers were blinded to clinical
data and histopathologic results. Image quality and lesion
conspicuity on eachmodality were evaluated using a three-point
scale (good-moderate-poor). Prior to performingmeasurements,
each reader also assessed the presence or absence of geometric
distortion, breathing and swallowing artefacts. All images were
evaluated in the transverse plane on a PACS workstation to
allow comparison between DWMRI acquired in the axial plane
and PET/CT images.
First, the fused T2-weighted, b1000 images and the
corresponding PET/CT fused images were identified and
matched, so as to enable measurements at the same anatom-
ic levels (Figs. 1 and 2). Then one reader drew a region of
interest (ROI) manually avoiding negative pixels by con-
touring the tumour area identified on the fused T2-weighted,
b1000 image and the respective ROI size was saved in a
DICOM format. This ROI with a predefined size was then
used for subsequent measurements on the anatomically
corresponding ADC maps and PET images of the same
patient. The size of the predefined ROI varied from 5 to
825 mm2 (mean=199 mm2) depending on the size of the
individual tumours on axial slices. In each head and neck
tumour, the measurements were performed at the largest
tumour size levels. The precise anatomic levels where the
measurements were performed were recorded. In a first
session, the first reader measured ADC and SUV values
for each lesion. Then, the second reader measured the same
parameters using the predefined ROI size and performing
the measurements at the predefined anatomic levels. Two
weeks later, measurements were repeated by the two readers,
independently, using the same methodology, so as to obtain a
second data set for each observer enabling assessment of intra-
observer agreement.
Statistical analysis
Statistical analysis was carried out using a commercially
available software program (SPSS software for Windows,
version 11.0, SPSS Inc., Chicago, IL, USA). Two methods
were used to assess intra- and inter-observer agreement for
SUV and ADC measurements [19–21]. Inter- and intra-
observer reproducibility of ADC and SUVof tumours were
determined as mean absolute difference (bias) and as 95 %
confidence interval (CI) of the mean difference (limits of
agreement), according to the methods of Bland and Altman
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Fig. 1 Anatomically matched
corresponding transverse slices
of inverted b1000 (a), PET (b),
fused T2-weighted, b1000 (c)
and fused PET/CT (d) images
of a 63-year-old male with
primary squamous cell
carcinoma of the hypopharynx
staged T4a N2c M0. Both PET/





region and both piriform
sinuses
Fig. 2 Anatomically matched
corresponding transverse slices
of inverted b1000 (a), PET (b),
fused T2-weighted, b1000 (c)
and fused PET/CT (d) images
of a 59-year-old patient with
primary undifferentiated
carcinoma of the nasopharynx
staged T4 N3 M0. Both PET/
CT and MRI fused images
allow correct anatomic
assessment of the right
nasopharyngeal carcinoma that
extends to the skull base,
parapharyngeal and
retropharyngeal space
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[19]. Relative bias (bias/mean value) and relative limits of
agreement (limits of agreement/mean value) were calculated.
Single measure intraclass correlation coefficients (ICC) were
calculated using the two-way random analysis of variance
(ANOVA) on average measures (ICC ranges 0.00–1.00 with
values closer to 1.00 representing better reproducibility) [19].
Interpretation of ICCwas categorized according to Landis and
Koch [20] as follows: <0, no reproducibility; 0.0–0.20, slight
reproducibility; 0.21–0.40, fair reproducibility; 0.41–0.60,
moderate reproducibility; 0.61–0.80, substantial reproducibil-
ity; and 0.81–1.00, almost perfect reproducibility. Pearson’s
correlation coefficient analysis was used to evaluate the
correlations between ADC (ADCmean, ADCmax, ADCmin)
and SUV (SUVmean, SUVmax, SUVmin) values. A p value of
less than 0.05 was considered as statistically significant.
Kruskal-Wallis one-way ANOVA [21] was used to detect
any statistically significant difference between ADC and
SUV values and ratios in primary versus recurrent tumours
and in different histologic tumour grades. Student’s t test was
used to compare significant difference between ADC at 1.5
and 3 T.
Results
Image quality and tumour detection
MRI image quality was considered as good in 20 patients
(61 %) and moderate in 13 patients (39 %). DW MRI image
quality did not depend on tumour location but on patient
cooperation during the MRI examination. Susceptibility
artefacts caused minor signal loss and minor to moderate
geometric distortion on DWI images in 23 of the 33 patients
(70 %); slight motion artefacts due to swallowing or breath-
ing were present in 13 patients (39 %). Regarding the
PET/CT, image quality was good in 27 cases (82 %) and
moderate in 6 cases (18 %). Artefacts due to dental amalgam
were seen in 14 patients (42 %) and swallowing/breathing
artefacts were present in 2 cases (6 %).
Conspicuity of all 34 HNSCC was rated as good on all
fused T2-weighted, b1000 images, ADC maps and PET/CT
images. All tumours showed a restricted diffusion with high
signal intensity on the b1000 images. Anatomic matching of
the fused T2-weighted, b1000 images and PET/CT images
was feasible in all tumours with comparable tumour conspi-
cuity on both modalities (Figs. 1 and 2).
ADC and SUV values
Table 1 summarizes the results of ADC (ADCmean, ADCmin)
and SUV (SUVmean, SUVmax) measurements of both
observers performed during the two readings. The mean
ADCmean and ADCmin values of all tumours together were
1.05±0.34×10−3mm2/s and 0.65±0.29×10−3mm2/s,
respectively. The mean SUVmean and SUVmax values of all
tumours were 9.86±3.82 and 12.80±5.00, respectively.
SUVmax values were higher for primary than for recurrent
tumours (p=0.025), whereas no statistically significant dif-
ference was observed regarding SUVmean, ADCmean and
ADCmin (p=0.109, p=0.897 and p=0.257, respectively).
There was no statistically significant difference for ADC-
mean values of HNSCC at 1.5 and 3 T (p=0.201).
Intra- and inter-observer agreement
The mean bias and the limits of agreement for intra- and
inter-observer measurements of SUV and ADC are dis-
played in the Bland–Altman plots of Figs. 3 and 4 and
summarized in Tables 2 and 3. ICC showed almost perfect
reproducibility for ADC and SUV values (Table 4).
Correlation of ADC and SUV values
There was no correlation between ADC values (ADCmean,
ADCmin, ADCmax) and SUV values (SUVmax, SUVmean or
SUVmin) (r −0.103, −0.051; p 0.552, 0.777) (Fig. 5).
ADC and SUV in relationship to the histologic grade
Table 5 summarizes the results of ADCmean and SUV-
mean of well, moderately and poorly differentiated
HNSCC. No significant correlation was seen between
the ADCmean and histologic grade (p=0.216) or between
SUVmean and histologic grade (p=0.425). There was,
however, a tendency of SUV to increase with dediffer-
entiation and a tendency of ADC to decrease with
dedifferentiation (Table 5).
Discussion
Most DWI sequences routinely used in head and neck
oncology are echo planar imaging (EPI)-based sequences
[8, 13, 17, 22, 23]. Although the quality of EPI DWI images
may be impaired by susceptibility artefacts, breathing or
swallowing, we were able to correctly localize the tumours
and to precisely position ROIs by fusing the b1000 and T2-
weighted sequences (Figs. 1 and 2). As recently shown, the
use of newer improved EPI technology, dedicated surface
coils and optimized sequences enables a maximal reduction
of EPI-related artefacts at a relatively high spatial resolution
[8, 23–27]. In addition, by carefully instructing the patient
not to move or swallow during image acquisition, good
quality DWI images may be obtained in the vast majority
of patients. In the current series, DWI images were of poor
quality only in 1 of 34 patients (3 % non-diagnostic DWI).
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As pointed out recently, in order to eliminate the effect of
possible distortion due to susceptibility artefacts, ADC meas-
urements should not be performed on ADC maps alone but
the anatomic information from T1- or T2-weighted sequences
should be taken into consideration when performing these
measurements [8, 27, 28]. In the current study ADC measure-
ments were performed using predefined ROIs saved in
DICOM format and fusing the b1000 and T2-weighted
images, thereby allowing optimal anatomic matching.
In our study we calculated the ADC of tumours from b
values of 0 and 1,000 s/mm2. Such high b values eliminate
the perfusion effect and have been used by most investiga-
tors for the evaluation of HNSCC [8, 17, 23, 24, 27–31].
The ADC values in the current series were obtained at 1.5
and 3 T. In theory, ADC values are independent of the
magnetic field strength [32]. Having measured at least two
different b values (such as b=0 and b=1,000 s/mm2), the
logarithm of the relative signal intensity of a tissue is plotted
Table 1 Comparison of ADC and SUV values in primary and recurrent HNSCC and for all tumours together
Biomarker All HNSCC (na=34) Primary HNSCC (na=24) Recurrent HNSCC (na=10) Primary vs recurrent
Mean±SD Mean±SD Mean±SD p values
ADCmean
b 1.05±0.34 1.03±0.30 1.12±0.42 >0.05
ADCmin
b 0.65±0.29 0.62±0.29 0.73±0.29 >0.05
SUVmean 9.86±3.82 10.68±3.72 7.90±3.45 >0.05
SUVmax 12.80±5.00 14.03±4.85 9.85±4.22 0.02
a Number of tumours
b ADC values are expressed in 10−3 mm2 /s
Fig. 3 Intra-observer reproducibility measurements in tumours of
ADCmean (a), SUVmean (b), ADCmin (c) and SUVmax (d). Bland–
Altman plots of relative difference values (in %) of measurements
(y-axis) against relative mean values (in %) of measurements (x-axis).
The mean absolute difference (bias) and 95 % CI of the mean difference
(1.96 SD) are equally indicated
Eur J Nucl Med Mol Imaging (2013) 40:842–852 847
on the y-axis against the b values on the x-axis. The slope of
the line fitted through the plots describes the ADC [32]. This
mono-exponential fitting is most often used in the literature
[8, 17, 23, 27, 32]. Several investigators have compared
ADC values of different tissues at different field strengths.
With one exception [33], the vast majority of studies
evaluating the influence of the magnetic field strength on
ADC measurements at 1.5, 3 and 7 T found no statistically
significant difference for ADC values either in the abdomen
[34, 35], or in the head and neck [36, 37], brain [25, 38] or
breast [38] provided that the parameters of the DWI
sequence used were identical. Data of the current series
showing no statistically significant difference between
ADC values of HNSCC at 1.5 and 3 T are in coherence
Fig. 4 Inter-observer reproducibility measurements in tumours of
ADCmean (a), SUVmean (b), ADCmin (c) and SUVmax (d). Bland–Alt-
man plots of relative difference values (in %) of measurements (y-axis)
against relative mean values (in %) of measurements (x-axis). The
mean absolute difference (bias) and 95 % CI of the mean difference
(1.96 SD) are equally indicated
Table 2 Inter-observer agree-
ments according to Bland and
Altman
LOA limits of agreement, IU in-
ternational unit
aADC values are expressed in
10−3mm2/s
bExpressed in % of average
values
Unit Mean Bias±LOA Lower LOA Upper LOA
ADCmean
a IU 1.054±0.335 −0.008±0.063 −0.106 0.090
%b 100±31.87 −0.77±6.01 −10.09 8.55
ADCmin
a IU 0.649±0.294 −0.015±0.067 −0.121 0.089
%b 100±45.36 −2.45±10.35 −18.63 13.73
SUVmean IU 9.86±3.82 −0.07±0.52 −0.88 0.73
%b 100±38.69 −0.75±5.23 −8.88 7.37
SUVmax IU 12.80±5.00 0.12±0.36 −0.45 0.68
%b 100±39.09 0.91±2.80 −3.51 5.32
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with the literature; in this retrospective series identical b
values and parameters were used so that any possible vari-
ation is negligible at most.
Although ADC measurements are increasingly used in
head and neck oncology, data regarding measurement repro-
ducibility are very scarce both for HNSCC [17] and for nodal
metastases from HNSCC [17, 22]. Our current data suggest
that intra- and inter-observer agreement for ADC measure-
ments are excellent (Figs. 3 and 4). Compared to the only
series to date evaluating observer variability in HNSCC [17],
we found a slightly superior inter-observer agreement (ICC=
0.95–0.96 versus reported 0.79) and a higher intra-observer
agreement for ADC values (ICC=0.98 versus reported 0.33)
[17]. These results may be explained by the use of predefined
ROIs matched for size and anatomic levels resulting in min-
imal inter- and intra-observer variability.
Currently, PET/CT is widely used for the pre-therapeutic
evaluation of HNSCC and for the assessment of treatment
response. In most studies, the most common quantitative
approach used is to measure SUVmax because this value is
not dependent on the size of the ROI used [13, 14, 39]. In
addition, in routine clinical practice, SUVmean is often equal-
ly reported. While SUVmax does not depend on the observer,
SUVmean may theoretically vary with the person who draws
the ROI [39]. Several investigators have shown an excellent
inter-observer reproducibility for SUVmax values for lung
cancer [40], sarcomas [41], breast cancer and, more recently,
for HNSCC [16]. In the current series, we found almost
perfect SUVmean and SUVmax reproducibility with ICC values
ranging from 0.97 to 0.99.
Both the ADC values and the SUV values of HNSCC in
the current study are similar to those reported by previous
investigators [13–15, 24, 29, 30, 42–46]. In our study, there
was no statistically significant association between the his-
tologic tumour grade and SUV or ADC values (Table 5),
although we observed a trend towards higher SUV and
lower ADC values in poorly differentiated as compared to
well differentiated HNSCC (Table 5). A similar trend has
been recently reported by another group [43].
Although SUV values mainly reflect cell proliferation,
whereas ADC values mainly reflect tissue cellularity, it is
still unclear whether both parameters may provide similar
information with respect to viable tumour cells or degree of
dedifferentiation. The question of whether these parameters
are statistically correlated or independent is gaining increas-
ing attention, as recent data suggest that both ADC and SUV
values may be correlated with cell proliferation and tumour
necrosis [1–4]. Our current study did not show a correlation
between SUVand ADC(1000) values in HNSCC, indicating
that these two biomarkers are independent biomarkers in
HNSCC. Similar observations were made in a previous
study [13, 14]; however, they were contradicted by another
group who found a significant negative correlation between
SUVmax and ADC(800) in 26 patients [15]. Correlating
SUVand ADC values of tumours requires performing meas-
urements on different imaging modalities at the same loca-
tion within the tumour. Ideally, this should be performed by
fusing MRI and PET/CT data sets. Although fusion of MRI
and PET/CT data sets may be feasible using currently avail-
able anatomy-based fusion software, the quality of such
multimodality fusion in the head and neck strongly depends
on the anatomic tumour location. As recently suggested, the
quality of data fusion above the hyoid bone may be good,
Table 3 Intra-observer agree-
ments according to Bland and
Altman
LOA limits of agreement, IU in-
ternational unit
aADC values are expressed in
10−3mm2/s
bExpressed in % of average
values
Unit Mean Bias±LOA Lower LOA Upper LOA
ADCmean
a IU 1.054±0.335 0.001±0.051 −0.078 0.080
%b 100±31.87 0.09±4.89 −7.48 7.65
ADCmin
a IU 0.649±0.294 −0.009±0.073 −0.122 0.105
%b 100±45.36 −1.37±11.31 −18.90 16.17
SUVmean IU 9.86±3.82 0.06±0.73 −1.07 1.19
%b 100±38.69 0.63±7.40 −10.84 12.10
SUVmax IU 12.80±5.00 0.19±0.72 −0.94 1.31
%b 100±39.09 1.46±5.62 −7.34 10.26
Table 4 Single measure ICC of overall measurements, indicating




ICC 95 % CI Precisiona Reproducibility
interpretationb
ADCmean 0.97 0.95–0.98 ±2 % Almost perfect
ADCmin 0.95 0.92–0.97 ±3 % Almost perfect
ADCmax 0.9 0.84–0.94 ±5 % Almost perfect
SUVmean 0.97 0.96–0.99 ±1 % Almost perfect
SUVmin 0.81 0.71–0.89 ±9 % Almost perfect
SUVmax 0.99 0.98–0.99 ±1 % Almost perfect
a Precision of ICC estimate is defined as one half length of 95 % CI
(expressed as percentage) and is a measure of reproducibility of ICC
estimate
b Reproducibility interpretation according to Landis and Koch [20]
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whereas fusion quality below the hyoid bone may be fair to
poor [47]. Until newly developed elastic fusion software
may become more widely available, visual correlation using
anatomic landmarks remains the most reliable way to pre-
cisely compare tumour levels on different imaging modali-
ties. Although the possible correlation between SUV and
ADC values is still a controversial issue, both parameters
may accurately predict response to chemotherapy [15, 48].
Additional work thus appears necessary in order to deter-
mine how to interpret these biomarkers in a complementary
fashion.
In conclusion, our study indicates that SUV and ADC
values are independent parameters in HNSCC. Measure-
ments of these two biomarkers were reproducible with al-
most perfect inter-observer and intra-observer agreements
for both methods. Neither SUV nor ADC values were able
to predict the histologic grade, although a trend towards
Fig. 5 Scatter plots represent results of linear regression between
ADCmean and SUVmean (a), ADCmean and SUVmax (b), ADCmin
and SUVmean (c) and ADCmin and SUVmax (d). ADCs are
expressed in 10−3mm2/s. For each scatter plot, the best-fit line
is shown. No statistically significant correlation was found
between ADC and SUV values
Table 5 ADC and SUV values of well, moderately and poorly differ-
entiated HNSCC (n=34)
Histologic grade n Mean±SD p
ADCmean
a Well differentiated 5 1.35±0.53 p=0.216
Moderately differentiated 21 1.02±0.26
Poorly differentiated 8 0.96±0.29
SUVmean Well differentiated 5 8.40±5.40 p=0.425
Moderately differentiated 21 10.00±3.30
Poorly differentiated 8 10.50±4.40
a ADC mean is expressed in 10−3 mm2 /s
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higher SUV and lower ADC values was observed in poorly
differentiated tumours. Further studies in larger patient
populations may address the question of whether the comple-
mentary use of SUV and ADC values could be useful in the
diagnosis of primary and recurrent HNSCC.
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